RELIEF Therapeutics Holding AG
RLF | SW
Overview
Corporate Details
- ISIN(s):
- CH1251125998
- LEI:
- 506700IT19260EVD7916
- Country:
- Switzerland
- Address:
- avenue de Sécheron 15, 1202 Genève
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
RELIEF Therapeutics Holding AG is a commercial-stage biopharmaceutical company focused on developing and commercializing novel, patent-protected therapies for rare and ultra-rare diseases with high unmet medical needs. The company's mission is to advance its pipeline of therapeutic candidates to provide patients with treatments that can significantly improve their condition and quality of life. Its strategy involves advancing clinical programs, such as its candidate for Epidermolysis Bullosa (RLF-TD011), and pursuing strategic transactions, including partnerships and business combinations, to accelerate development and market access for its products.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for RELIEF Therapeutics Holding AG.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-14 07:00 |
Report Publication Announcement
Relief Therapeutics Publishes 2025 Half-Year Report
|
English | 9.0 KB | |
| 2025-08-14 02:00 |
Report Publication Announcement
Relief Therapeutics Publishes 2025 Half-Year Report
|
English | 6.8 KB | |
| 2025-08-11 07:00 |
Report Publication Announcement
Relief Therapeutics Advances Publication of 2025 Half-Year Report
|
English | 6.9 KB | |
| 2025-08-11 02:00 |
Report Publication Announcement
Relief Therapeutics Advances Publication of 2025 Half-Year Report
|
English | 4.8 KB | |
| 2025-07-29 07:00 |
M&A Activity
Relief Therapeutics Announces Proposed Business Combination with NeuroX, succes…
|
English | 15.9 KB | |
| 2025-07-29 02:00 |
M&A Activity
Relief Therapeutics Announces Proposed Business Combination with NeuroX, succes…
|
English | 13.6 KB | |
| 2025-06-20 07:00 |
Legal Proceedings Report
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
|
English | 10.7 KB | |
| 2025-06-20 02:00 |
Regulatory News Service
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
|
English | 8.5 KB | |
| 2025-06-12 11:00 |
Post-Annual General Meeting Information
Relief Therapeutics Announces Results of Annual General Meeting
|
English | 10.5 KB | |
| 2025-06-12 02:00 |
Post-Annual General Meeting Information
Relief Therapeutics Announces Results of Annual General Meeting
|
English | 8.3 KB | |
| 2025-05-22 07:00 |
Regulatory News Service
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD0…
|
English | 11.7 KB | |
| 2025-05-22 02:00 |
Regulatory News Service
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD0…
|
English | 9.5 KB | |
| 2025-05-15 07:00 |
Pre-Annual General Meeting Information
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
|
English | 8.6 KB | |
| 2025-05-15 02:00 |
Pre-Annual General Meeting Information
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
|
English | 6.2 KB | |
| 2025-04-10 07:00 |
Annual Report
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
|
English | 8.8 KB |
Automate Your Workflow. Get a real-time feed of all RELIEF Therapeutics Holding AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for RELIEF Therapeutics Holding AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
